Bayer image

Novartis and Bayer seek to oppose High Court ruling over NHS decision to use cheaper drug

pharmafile | October 16, 2018 | News story | Manufacturing and Production Bayer, CCG, NHS, Novartis, avastin, wet AMD 

Swiss multinational Novartis have joined German pharma firm Bayer in appealing a High Court ruling over 12 NHS clinical commissioning groups (CCGs) decision to use a cheaper alternative to the two company’s treatments for wet AMD.

While courts backed the NHS commissioning bodies’ decision to use Avastin to treat the leading cause of age-related vision loss in the UK, wet AMD, in September of this year; Novartis and Bayer, who produce more expensive alternatives, Lucentis and Eylea, are seeking permission to appeal the British court’s ruling.

The ruling allowed NHS hospitals to use Avastin, a drug approved for the treatment of cancer, which is 30 times cheaper than Novartis and Bayer’s treatments, instead of Novartis and Bayer’s medications.

However the multinational drugmakers are seeking to appeal the decision. A spokesperson for Novartis said: “Today, people living with wet AMD are now being asked to compromise on the assured quality and safety of their treatment, purely on the basis of cost. This is inappropriate and unnecessary. In the future, on the basis of this judgment, it may be people living with cancer, diabetes, or any other long-term condition being asked to compromise on the quality and safety of their treatments.”

Louis Goss

Related Content

Novartis shares new data about Fabhalta for IgAN treatment

Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …

NICE recommends migraine treatment for NHS use

The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s …

Bayer and Aignostics to collaborate for AI oncology research

Bayer and Aignostics have announced that they have entered into a strategic collaboration for several …

Latest content